If you aim to disrupt an industry, you must be willing to disrupt yourself

If you aim to disrupt an industry, you must be willing to disrupt yourself

Why embracing digital transformation in drug development is the Leader’s’ job.

Technology is an essential enabler for almost everything a biotech or pharma does in clinical trials:

  • innovation,
  • product management,
  • operations.

While in the past, company leaders may have not needed an in-depth understanding of technology challenges and opportunities, covid made us realize that this approach will no longer work.

With technology you can win or lose when it comes to your clinical development! Every leader needs to understand what technology can do for the company and how.

At the same time, in these challenging times, we must care so much more about our team –

  • their productivity,
  • connectivity,
  • stress levels and much more.

A true leader needs to understand how technology impacts everyone’s lives. We extend our care beyond our own team to the customers and partners. And it is essential to bridge the communication gap between every stakeholder in the trial.

It is the responsibility of the company’s leadership to help their people, their customers and partners to adapt to and adopt the many changes that technology will enforce, engage people with a huge degree of empathy and help them to embrace the changes and co-own the transformation.

At IAG, Image Analysis Group, we saw how our cloud based platform DYNAMIKA helped to erase many boundaries and distances. When we embark on a new trial, the imaging sites, project managers, investigators, radiologists, sponsors must be connected and information must flow fluently allowing real-time decisions and full transparency of every stakeholder.

Regardless of geography, size of the biotech or pharma, level of education in modern clinical trial infrastructure, we must ensure transparency of information and embrace a new normal of remote connectivity.

Today, by force of the global pandemic, the companies planning or running clinical trials need to think globally.

This requires leaders who are not afraid to think and engage globally, who will expose themselves and their teams to this new digital era thinking and find partners to support them.

We believe that IAG, Image Analysis Group is the right partner to anyone planning or running a global multi-centre clinical trial that requires use of imaging in the patient selection or to measure efficacy of an emerging therapeutic.

We believe that this is just the beginning!

We are standing on step 1 of the new digital age of clinical trials and the magnitude of the covid forced transformation will require leadership of biotech and pharma to build on what we learnt over the past 12 months and manage the complex digital world we are plunging ourselves into!

Courage and commitment will have us reinvent ourselves and champion the new digital age of clinical development.

——————————-

If you are planning a new clinical trial, this is where we can help to think through the trial design, optimal use of imaging biomarkers, use of cloud platform for imaging data central review and use of AI – to assess complex manifestations of the new treatments. Email to: imaging.experts@ia-grp.com

About IAG, Image Analysis Group

IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.

Views
Events